In patients without TMZ treatment, high BICD1 expression still showed significant impact (P=0.009929) on poor overall survival, while high MGMT expression did not show significance (P=0.341587) (Figure 6B), which was compatible with the current knowledge that MGMT is a specific biomarker for predicting the response to TMZ treatment in glioma patients [35]. This evidence concerns the gene MGMT and central nervous system cancer.